3D Systems Announces Establishment of Medical Advisory Board & Appointment of Dr. Stephen K. Klasko as Chair
May 16 2022 - 8:30AM
Today, 3D Systems (NYSE:DDD) announced the formation of the
company’s first Medical Advisory Board (MAB) and the appointment of
Stephen K. Klasko, MD, MBA as Chair. The primary mission of
the MAB will be to provide strategic input, guidance, and
recommendations for the company’s emerging regenerative medicine
efforts as they begin moving from research into advanced
development and, ultimately, into human application. The MAB
will comprise a diverse spectrum of skill sets and experiences
ranging from scientific expertise to commercial application,
including advising on the formation of key partnerships to reduce
program risks and accelerate the attainment of program objectives.
Dr. Klasko, who will serve as the MAB’s first Chair, is one of
the most respected executives in the healthcare industry today,
known for bridging the entrepreneurial mindset of Silicon Valley
with the current healthcare ecosystem. Most recently, he led
Jefferson Health to become one of the fastest-growing academic
health centers in the United States, as president and CEO of Thomas
Jefferson University and Jefferson Health. Over Dr. Klasko’s
eight-year tenure, Jefferson grew from roughly $1 billion in
revenue to over $9 billion, dramatically expanding the
institution’s capabilities and reach - establishing one of the
nation’s largest and most advanced telemedicine faculty-based
healthcare to bring healthcare to millions in need.
Over the course of his accomplished career, Dr. Klasko has
served as Dean of two medical schools and CEO of three health
systems. He is deeply committed to transforming health care from
its traditional focus on “sick care,” to a resilient, proactive
system of “healthcare at any address” – designed to bend the cost
curve through innovation, make quality care more accessible, and
move population health, social determinants, and predictive
analytics from philosophic exercises to the mainstream of clinical
care and payment models. Dr. Klasko is one of the leading voices in
the nation, championing the transformation of healthcare
systems in partnership with digital technology innovators in the
quest for a very different and brighter future.
Commenting on the creation of the MAB and Dr. Klasko's
appointment, Dr. Jeffrey Graves, president and CEO, 3D Systems,
commented, "This is a pivotal time in our company’s history where
each day we can see more clearly the potential of regenerative
medicine to positively impact humanity and the key role our
bioprinting technology can play in the future of
humankind. The MAB will provide key input, guidance, and
support in making this vision a reality. We are blessed
with Dr. Klasko’s willingness to chair this group and help
guide its formation and operation. Steve is an inspirational
leader who articulates a compelling vision for the healthcare
industry, including the transformational potential of medical
technology to improve patient outcomes, expand access, and reduce
medical costs. He embodies a deep passion for entrepreneurism
and inclusiveness that has yielded remarkable results throughout
his career. In recognition of his accomplishments, in 2020 he was
named by the World Economic Forum as their first Distinguished
Fellow, in which he has provided key insights to business and
political leaders on the future of healthcare and the digital
economy in their annual meetings held in Davos,
Switzerland. Under Steve's leadership, we look forward to
expanding the MAB in the future as our efforts continue to gain
momentum."
In addition to authoring five books, numerous articles, and
blogs, Dr. Klasko’s track record of visionary leadership has been
widely recognized over the course of his career, including his
designation as #2 on Modern Healthcare’s “100 Most Influential
Individuals,” Fast Company's Most Creative People in Business,
Ernst & Young’s “Entrepreneur of the Year” in 2018, and
Becker’s Hospital Review’s “100 Great Leaders in Healthcare."
Since he retired from Jefferson Health earlier this year, Dr.
Klasko has assumed the role of Executive in Residence for
General Catalyst where he is putting into action the "health
assurance" model based on the book he wrote with Hemant Taneja,
managing partner of GC, entitled "UnHealthcare: A Manifesto for
Health Assurance." Since 2008, Dr. Klasko has also been a
director of Teleflex (NYSE:TFX) where he has served on both the
governance and audit committees.
Forward-Looking StatementsCertain statements
made in this release that are not statements of historical or
current facts are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of the company to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. In many cases, forward-looking statements can be
identified by terms such as "believes," "belief," "expects," "may,"
"will," "estimates," "intends," "anticipates" or "plans" or the
negative of these terms or other comparable terminology.
Forward-looking statements are based upon management’s beliefs,
assumptions, and current expectations and may include comments as
to the company’s beliefs and expectations as to future events and
trends affecting its business and are necessarily subject to
uncertainties, many of which are outside the control of the
company. The factors described under the headings "Forward-Looking
Statements" and "Risk Factors" in the company’s periodic filings
with the Securities and Exchange Commission, as well as other
factors, could cause actual results to differ materially from those
reflected or predicted in forward-looking statements. Although
management believes that the expectations reflected in the
forward-looking statements are reasonable, forward-looking
statements are not, and should not be relied upon as a guarantee of
future performance or results, nor will they necessarily prove to
be accurate indications of the times at which such performance or
results will be achieved. The forward-looking statements included
are made only as of the date of the statement. 3D Systems
undertakes no obligation to update or revise any forward-looking
statements made by management or on its behalf, whether as a result
of future developments, subsequent events or circumstances or
otherwise, except as required by law.
About 3D Systems More than 30 years ago, 3D
Systems brought the innovation of 3D printing to the manufacturing
industry. Today, as the leading additive manufacturing solutions
partner, we bring innovation, performance, and reliability to every
interaction - empowering our customers to create products and
business models never before possible. Thanks to our unique
offering of hardware, software, materials, and services, each
application-specific solution is powered by the expertise of our
application engineers who collaborate with customers to transform
how they deliver their products and services. 3D Systems’ solutions
address a variety of advanced applications in healthcare and
industrial markets such as medical and dental, aerospace &
defense, automotive, and durable goods. More information on the
company is available at www.3dsystems.com.
Investor Contact: investor.relations@3dsystems.comMedia Contact:
press@3dsystems.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/eca37f69-0731-476f-b324-9f6d586b9855
3D Systems (NYSE:DDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
3D Systems (NYSE:DDD)
Historical Stock Chart
From Apr 2023 to Apr 2024